{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T07:57:10Z","timestamp":1648972630865},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1097\/iop.0b013e3182776f32","type":"journal-article","created":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T09:54:18Z","timestamp":1355824458000},"page":"e114-e115","source":"Crossref","is-referenced-by-count":2,"title":["Complete Response to Second Line Paclitaxel Every 2 Weeks of Eyelid Kaposi Sarcoma"],"prefix":"10.1097","volume":"29","author":[{"given":"Anna Elisabetta","family":"Brunetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Guarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Minoia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Sabatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Marech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Silvestris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-28-20210129","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF01830024","article-title":"Idiopatisches multiples Pigmentsarkom der Haut.","volume":"4","author":"Kaposi","year":"1872","journal-title":"Arch Dermatol Syph"},{"key":"R2-28-20210129","first-page":"311","article-title":"AIDS-related Kaposis sarcoma: principal pathogenic mechanisms.","volume":"18","author":"Silvestris","year":"1999","journal-title":"J Exp Clin Cancer Res"},{"key":"R3-28-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1746-1596-3-31","article-title":"Histological variants of cutaneous Kaposi sarcoma.","volume":"3","author":"Grayson","year":"2008","journal-title":"Diagn Pathol"},{"key":"R4-28-20210129","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2407-8-190","article-title":"Kaposi sarcoma in unusual locations.","volume":"8","author":"Pantanowitz","year":"2008","journal-title":"BMC Cancer"},{"key":"R5-28-20210129","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0161-6420(92)31841-X","article-title":"Treatment of ocular adnexal Kaposis sarcoma in acquired immune deficiency syndrome.","volume":"99","author":"Dugel","year":"1992","journal-title":"Ophthalmology"},{"key":"R6-28-20210129","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1468-3083.2006.01730.x","article-title":"Combination of vinblastine and bleomycin as first line therapy in advanced classic Kaposis sarcoma.","volume":"20","author":"Brambilla","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R7-28-20210129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/039463200601900202","article-title":"Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposis sarcoma: a systematic review.","volume":"19","author":"Di Trolio","year":"2006","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R8-28-20210129","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/sj.jid.5701215","article-title":"Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposis sarcoma: a multicenter study.","volume":"128","author":"Di Lorenzo","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R9-28-20210129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cncr.10634","article-title":"Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.","volume":"95","author":"Tulpule","year":"2002","journal-title":"Cancer"},{"key":"R10-28-20210129","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R11-28-20210129","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","article-title":"Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposis sarcoma: results of a randomized phase III clinical trial.","volume":"16","author":"Northfelt","year":"1998","journal-title":"J Clin Oncol"},{"key":"R12-28-20210129","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1200\/JCO.1998.16.2.683","article-title":"Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposis sarcoma. International Pegylated Liposomal Doxorubicin Study Group.","volume":"16","author":"Stewart","year":"1998","journal-title":"J Clin Oncol"},{"key":"R13-28-20210129","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2133.1993.tb00490.x","article-title":"The therapeutic effect of intralesional interferon in classical Kaposis sarcoma.","volume":"129","author":"Trattner","year":"1993","journal-title":"Br J Dermatol"},{"key":"R14-28-20210129","first-page":"675","article-title":"Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposis sarcoma.","volume":"29","author":"Silvestris","year":"2009","journal-title":"Anticancer Res"},{"key":"R15-28-20210129","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4049\/jimmunol.165.1.509","article-title":"Mechanism of paclitaxel activity in Kaposis sarcoma.","volume":"165","author":"Sgadari","year":"2000","journal-title":"J Immunol"},{"key":"R16-28-20210129","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/cncr.21791","article-title":"Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection.","volume":"106","author":"Fardet","year":"2006","journal-title":"Cancer"},{"key":"R17-28-20210129","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1002\/cncr.25362","article-title":"Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.","volume":"116","author":"Cianfrocca","year":"2010","journal-title":"Cancer"}],"container-title":["Ophthalmic Plastic & Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IOP.0b013e3182776f32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:52:18Z","timestamp":1620957138000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002341-201309000-00028"}},"subtitle":["A Case Report"],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/iop.0b013e3182776f32","relation":{},"ISSN":["0740-9303"],"issn-type":[{"value":"0740-9303","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}